Search results for: 'Multi-omics Data Management Solutions'

The report explores the transformation of obesity care from generalized BMI-based treatment to AI-enabled precision metabolic management. The study highlights how obesity is increasingly recognized as a heterogeneous, multi-pathway disease influenced by genetic, neurobehavioral, metabolic, and environmental factors, requiring personalized therapeut...

Biological age tracking is emerging as a complementary approach to understanding human health, offering a more nuanced assessment of physiological state than chronological age alone. This report examines the evolving landscape of biological aging platforms, with a focus on molecular and omics-based technologies including epigenetic, proteomic, tran...

This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabol...

The evolving IT landscape has played a transformative role in the field of life sciences, enabling a reliance on real-world evidence (RWE) solutions. With growing competition and the demand for precision in decision-making, pharmaceutical companies, healthcare providers, and technology organizations have realized the need for real-world data (RWD) ...

The regulatory technology market in life sciences has, over the last five years, quietly transformed from a back-office category dominated by document repositories and submission publishing tools to one of the most consequential software segments serving the pharmaceutical, biotech, and medical device industries. What started in the late 1990s as a...

Obesity and diabetes are areas of growing concern across both, developed and developing countries. The rising geriatric population is likely to contribute to an increased prevalence of obesity and diabetes across the global landscape. Biomarker research is likely to facilitate the emergence of novel tools that may be useful for enhanced management ...

Over the last 3-5 years, growing cost pressure on healthcare and pharmaceutical companies and a significant shift towards outcome based healthcare approach have resulted in companies increasingly adopting real world data and evidence solutions to optimize their operation and cost using analytics. Earlier, applications of RWE were largely limited to...

Europe’s life sciences sector is approaching a defining inflection point in 2026, as major regulatory and policy reforms converge to reshape pharma, diagnostics, life sciences IT, biotechnology, and the bioeconomy. Together, these frameworks open clear growth pathways across the value chain: the Clinical Trials Regulation (CTR) and European Health ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming AI-enabled discovery, precision diagnostics, cell engineering, targeted therapeutics, vaccines, and skin health across oncology, metabolic disease, rare disorders, neuropsychiatry, and ne...